chronic lymphoproliferative disorder of NK-cells
diseaseOn this page
Also known as chronic NK lymphocytosischronic NK-cell lymphocytosischronic NK-large granular lymphocyte lymphoproliferative disorderchronic NK-LGL lymphoproliferative disorderCLPD-NKCNKLindolent large granular NK-cell lymphoproliferative disorderindolent NK-cell lymphoproliferative disordernatural killer-cell large granular lymphocyte leukaemianatural killer-cell large granular lymphocyte leukemiaNK-cell large granular lymphocyte lymphocytosisNK-cell lineage granular lymphocyte proliferative disorderNK-LGL leukaemiaNK-LGL leukemiaNK-LGLLNK-type lymphoproliferative disorder of granular lymphocytes
Summary
chronic lymphoproliferative disorder of NK-cells (MONDO:0004234) is a disease and 7 clinical trials. Top therapeutic interventions include thalidomide. A subtype of neoplasm of mature T-cells or NK-cells — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | chronic lymphoproliferative disorder of NK-cells |
| Mondo ID | MONDO:0004234 |
| Orphanet | 512017 |
| DOID | DOID:7465 |
| ICD-11 | 921755282 |
| NCIT | C39591 |
| SNOMED CT | 722955006 |
| UMLS | C1512709 |
| MedGen | 268922 |
| GARD | 0022072 |
| Is cancer (heuristic) | no |
Also known as: chronic lymphoproliferative disorder of NK-cells · chronic NK lymphocytosis · chronic NK-cell lymphocytosis · chronic NK-large granular lymphocyte lymphoproliferative disorder · chronic NK-LGL lymphoproliferative disorder · CLPD-NK · CNKL · indolent large granular NK-cell lymphoproliferative disorder · indolent NK-cell lymphoproliferative disorder · natural killer-cell large granular lymphocyte leukaemia · natural killer-cell large granular lymphocyte leukemia · NK-cell large granular lymphocyte lymphocytosis · NK-cell lineage granular lymphocyte proliferative disorder · NK-LGL leukaemia · NK-LGL leukemia · NK-LGLL · NK-type lymphoproliferative disorder of granular lymphocytes
Data availability: 2 cell lines.
Disease family
This is a subtype of neoplasm of mature T-cells or NK-cells. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells › chronic lymphoproliferative disorder of NK-cells
Related subtypes (3): mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified, EBV-positive T-cell lymphoproliferative disorder of childhood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04453345 | PHASE2/PHASE3 | UNKNOWN | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
| NCT06530550 | PHASE2 | RECRUITING | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas |
| NCT06530576 | PHASE2 | RECRUITING | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia |
| NCT06716658 | PHASE2 | RECRUITING | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas |
| NCT02863692 | Not specified | RECRUITING | Registry of the German CLL Study Group |
| NCT05978141 | Not specified | RECRUITING | A Registry for People With T-cell Lymphoma |
| NCT07019766 | Not specified | RECRUITING | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| THALIDOMIDE | 4 | 1 |
| CHEMBL15720 | 0 | 1 |
| CHEMBL426123 | 0 | 1 |
Related Atlas pages
- Drugs: Thalidomide